Letrado, PatriciaCorsini, BrunoDíez-Martínez, RobertoBustamante, NoemíYuste, Jose EnriqueGarcía, Pedro2020-11-172020-11-172018Future Microbiol . 2018 Sep;13(11):1215-1223.http://hdl.handle.net/20.500.12105/11357To test the synergistic effect of Cpl-711 endolysin and antibiotics for antipneumococcal activity. A combination of Cpl-711 and different antibiotics (amoxicillin, cefotaxime, levofloxacin and vancomycin) was tested in a checkerboard assay against several multidrug-resistant Streptococcus pneumoniae strains. Mouse and zebrafish models of pneumococcal sepsis were used to confirm the in vitro data. The activity of Cpl-711 combined with amoxicillin or cefotaxime was synergistic in the bactericidal effect against a serotype 23F multiresistant clinical isolate of S. pneumoniae. Synergy between Cpl-711 and cefotaxime was validated using both mouse and zebrafish models. Combination of Cpl-711 and cefotaxime may help in the treatment of diseases caused by multiresistant pneumococcal strains.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/Streptococcus pneumoniaeantibiotic multidrug-resistantendolysinmouse modelsynergyzebrafish modelDrug Resistance, Multiple, BacterialAnimalsAnti-Bacterial AgentsCefotaximeDisease Models, AnimalDrug SynergismFemaleMiceMice, Inbred BALB CMuramidasePneumococcal InfectionsRecombinant Fusion ProteinsSepsisStreptococcus PhagesStreptococcus pneumoniaeZebrafishAttribution-NonCommercial-NoDerivatives 4.0 Internacional30238774131215-122310.2217/fmb-2018-00771746-0921Future microbiologyopen access